ATE419236T1 - 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten - Google Patents

3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten

Info

Publication number
ATE419236T1
ATE419236T1 AT02743489T AT02743489T ATE419236T1 AT E419236 T1 ATE419236 T1 AT E419236T1 AT 02743489 T AT02743489 T AT 02743489T AT 02743489 T AT02743489 T AT 02743489T AT E419236 T1 ATE419236 T1 AT E419236T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
muscarinic receptor
azabicyclo
derivatives
hexane derivatives
Prior art date
Application number
AT02743489T
Other languages
English (en)
Inventor
Anita Mehta
Arundutt Silamkoti
Jang Gupta
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of ATE419236T1 publication Critical patent/ATE419236T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Plant Substances (AREA)
AT02743489T 2002-07-08 2002-07-08 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten ATE419236T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/002663 WO2004004629A2 (en) 2002-07-08 2002-07-08 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
ATE419236T1 true ATE419236T1 (de) 2009-01-15

Family

ID=30011691

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02743489T ATE419236T1 (de) 2002-07-08 2002-07-08 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten
AT03762827T ATE342253T1 (de) 2002-07-08 2003-04-11 Azabicycloderivate als antagonisten des muscarinischen rezeptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03762827T ATE342253T1 (de) 2002-07-08 2003-04-11 Azabicycloderivate als antagonisten des muscarinischen rezeptors

Country Status (19)

Country Link
US (2) US7399779B2 (de)
EP (2) EP1546099B1 (de)
JP (2) JP2006502985A (de)
CN (2) CN1668585A (de)
AT (2) ATE419236T1 (de)
AU (2) AU2002345266B2 (de)
BR (2) BR0215801A (de)
CA (2) CA2492121A1 (de)
CY (1) CY1105879T1 (de)
DE (2) DE60230683D1 (de)
DK (1) DK1551803T3 (de)
EA (3) EA200500173A1 (de)
ES (1) ES2274275T3 (de)
MX (2) MXPA05000434A (de)
NZ (2) NZ537584A (de)
PT (1) PT1551803E (de)
SI (1) SI1551803T1 (de)
WO (2) WO2004004629A2 (de)
ZA (1) ZA200500951B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537584A (en) * 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) * 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
ES2634841T3 (es) * 2003-10-14 2017-09-29 Pfizer Products Inc. Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina
EP1746998A1 (de) * 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Kombinationstherapie für symptome der unteren harnwege
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006003587A2 (en) * 2004-07-01 2006-01-12 Ranbaxy Laboratories Limited Solid oral dosage forms of azabicyclo derivatives
WO2006016245A1 (en) * 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006032994A2 (en) * 2004-09-24 2006-03-30 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1796667A2 (de) * 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Muscarinische rezeptor-antagonisten
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (de) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituierte azabicyclo[3.1.0]hexanderivate als antagonisten des muskarinrezeptors
WO2007039884A1 (en) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
WO2007045979A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2007110782A1 (en) 2005-12-30 2007-10-04 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20100222393A1 (en) 2005-12-30 2010-09-02 Naresh Kumar Muscarinic receptor antagonists
WO2008075321A2 (en) * 2006-12-21 2008-06-26 Ranbaxy Laboratories Limited Modified-release formulations of azabicyclo derivatives
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
JP2020506895A (ja) * 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
CN111317754B (zh) * 2018-12-13 2022-02-18 泰州医药城国科化物生物医药科技有限公司 一种北豆根总碱的制备方法及应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490714A (en) 1947-05-13 1949-12-06 Du Pont Preparation of diazoacetic esters
NL267508A (de) 1960-07-26
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5001160A (en) 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
RU2049777C1 (ru) 1989-08-16 1995-12-10 Пфайзер Инк. Азабицикло-хинолон-карбоновые кислоты или их фармацевтически приемлемые кислотно-аддитивные соли и промежуточные продукты для их получения
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5281601A (en) 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
FR2659323B1 (fr) * 1990-03-07 1992-06-12 Synthelabo Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
JPH0492921A (ja) 1990-08-03 1992-03-25 Fujitsu Ltd 指数関数演算器
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JPH0635958A (ja) 1992-07-14 1994-02-10 Hitachi Ltd 語句検索方法
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
DE59306269D1 (de) 1993-02-24 1997-05-28 Siemens Ag Sperrwandler-Schaltnetzteil mit einem Halbleiterschaltelement geringer Spannungsfestigkeit
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
EP0823423B1 (de) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituierte piperidinderivate
CA2179574A1 (en) 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
DE69615214T2 (de) 1995-10-13 2002-06-27 Banyu Pharmaceutical Co., Ltd. Substituierte heteroaromatische derivate
WO1997045414A1 (en) 1996-05-31 1997-12-04 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
EP0920313A1 (de) 1996-07-01 1999-06-09 Sepracor, Inc. Verfahren und zusammensetzungen zur behandlung der harninkontinenz mit enantiomerisch angereicherten (s,s)-glycopyrolaten
WO1998000132A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,s)-glycopyrrolate
EP0909163A4 (de) 1996-07-01 1999-06-09 Sepracor Inc Verfahren und mittel zur behandlung der harninkontinenz unter hauptsaechlicher verwendung des (s,r)-glycopyrrolat enantiomers
EP0932401A1 (de) 1996-07-01 1999-08-04 Sepracor, Inc. Methoden und zusammensetzungen zur behandlung von harninkontiniez mittels enantiomerishc angereichertem (r,r)-glycopyrrolat
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
EP1001764A4 (de) 1997-05-29 2005-08-24 Merck & Co Inc Heterozyklische amide als zelladhäsionshemmern
US6319920B1 (en) 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
MXPA02005596A (es) 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
EP1289965B1 (de) 2000-05-25 2005-10-26 F. Hoffmann-La Roche Ag Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
HUP0302015A2 (hu) 2000-05-25 2003-10-28 F. Hoffmann-La Roche Ag. Helyettesített 1-aminoalkil-laktámok és felhasználásuk muszkarin receptor antagonistaként
WO2002006241A1 (en) 2000-06-14 2002-01-24 Muscagen Limited 1, 2, 3, 5 -tetrahydrobenzo`c!azepin-4-one derivatives having muscarinic antagonist activity
AU6610001A (en) 2000-06-27 2002-01-08 S A L V A T Lab Sa Carbamates derived from arylalkylamines
CA2415468A1 (en) 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
CN1250545C (zh) 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
WO2002083863A2 (en) * 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
RU2004110717A (ru) 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
PL370765A1 (en) * 2001-12-03 2005-05-30 F.Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
EP1453806B1 (de) * 2001-12-03 2007-12-19 F. Hoffmann-La Roche Ag Aminotetralinderivate, antagonisten von muscarinrezeptoren
NZ537584A (en) 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
WO2004014853A1 (en) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
AU2002321711A1 (en) 2002-08-09 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有3,6−二置換アザビシクロ(3.1.0)ヘキサン誘導体
US7232835B2 (en) * 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
AU2002356369A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Xanthine derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004069835A1 (en) 2003-02-07 2004-08-19 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2521788A1 (en) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
FR2855805B1 (fr) 2003-06-06 2005-08-05 Vallourec Vitry Element de structure pour vehicule, capable d'un meilleur comportement aux chocs
EP1746998A1 (de) 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Kombinationstherapie für symptome der unteren harnwege
EP1796667A2 (de) 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Muscarinische rezeptor-antagonisten
WO2006064304A1 (en) 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists

Also Published As

Publication number Publication date
EA009942B1 (ru) 2008-04-28
JP2006502985A (ja) 2006-01-26
EP1546099A4 (de) 2006-08-02
AU2002345266A1 (en) 2004-01-23
EA200500172A1 (ru) 2005-08-25
EP1551803A1 (de) 2005-07-13
MXPA05000435A (es) 2005-04-19
SI1551803T1 (sl) 2007-02-28
US7399779B2 (en) 2008-07-15
EP1551803B8 (de) 2006-12-13
EP1546099A2 (de) 2005-06-29
AU2003226579B2 (en) 2009-01-22
EA007932B1 (ru) 2007-02-27
ZA200500951B (en) 2006-07-26
CY1105879T1 (el) 2011-02-02
CN1681784A (zh) 2005-10-12
AU2002345266B2 (en) 2009-07-02
CN1668585A (zh) 2005-09-14
NZ537585A (en) 2006-07-28
DE60309057D1 (de) 2006-11-23
NZ537584A (en) 2006-07-28
EA200501595A1 (ru) 2006-06-30
BR0312572A (pt) 2005-05-10
PT1551803E (pt) 2007-01-31
HK1082728A1 (en) 2006-06-16
BR0215801A (pt) 2005-05-10
US20060111425A1 (en) 2006-05-25
EA200500173A1 (ru) 2005-08-25
DE60309057T2 (de) 2007-04-12
ES2274275T3 (es) 2007-05-16
AU2003226579A1 (en) 2004-01-23
DE60230683D1 (de) 2009-02-12
MXPA05000434A (es) 2005-04-19
CA2491998A1 (en) 2004-01-15
US20070004791A1 (en) 2007-01-04
EP1551803B1 (de) 2006-10-11
CN100519526C (zh) 2009-07-29
HK1079783A1 (en) 2006-04-13
WO2004004629A2 (en) 2004-01-15
JP2005535655A (ja) 2005-11-24
EP1546099B1 (de) 2008-12-31
CA2492121A1 (en) 2004-01-15
WO2004005252A1 (en) 2004-01-15
WO2004004629A3 (en) 2004-05-21
DK1551803T3 (da) 2007-02-19
US7544708B2 (en) 2009-06-09
ATE342253T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
DE60309057D1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
TW200505903A (en) CGRP receptor antagonists
MX2009012579A (es) Antagonistas piridil piperidina del receptor de orexina.
WO2004091514A3 (en) Cgrp receptor antagonists
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
DE60226906D1 (de) 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
AU2002353286A1 (en) 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2006041830A3 (en) Cgrp receptor antagonists
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
DE60225195D1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten
DE60313898D1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
WO2006035282A3 (en) Muscarinic receptor antagonists
WO2006044449A3 (en) Cgrp receptor antagonists
HK1079708A1 (zh) 可用作毒蕈碱性受体拮抗剂的3,6-二取代氮杂二环[3.1.10]己烷衍生物
WO2006018708A3 (en) Pyrrolidine derivatives as muscarinic receptor antagonists
WO2006032994A3 (en) Muscarinic receptor antagonists
DE602004018844D1 (de) Als antagonisten des muscarinrezeptors geeignete xanthinderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties